MisterEnzo, There are very few of us on the board, hence not a lot of posts. Most of us who hold shares are also on the company's email list, so I get most of my information that way or from my brokerage.
Happy to welcome you as a fellow shareholder. Jonathan Adams seems to be doing the right things (IMHO) to move the ascites drug forward. Technically, there are more drug assets on the books from the company's days as NNAB, but he is concentrating on getting the most advanced one across the goal line.
News 
Market Data 
Discover 
